Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅰb Study Evaluating the Safety, Tolerability and Pharmacokinetics of Pegylated Recombinant Human Endostatin (PEG-ENDO) in Subjects With Advanced / Metastatic Non-small Cell Lung Cancer (NSCLC) or Other Solid Tumors

NCT04413227 is registered in ClinicalTrials.gov with Jiangsu Simcere Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04413227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04413227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅰb Study Evaluating the Safety, Tolerability and Pharmacokinetics of Pegylated Recombinant Human Endostatin (PEG-ENDO) in Subjects With Advanced / Metastatic Non-small Cell Lung Cancer (NSCLC) or Other Solid Tumors
Lead sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
April 2, 2020
Completion date
September 30, 2021
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc, solid tumor